New News information at Drug Development Technology New and updated information from News listed on www.drugdevelopment-technology.com http://www.drugdevelopment-technology.com/ en-us http://www.drugdevelopment-technology.com/ New News information at Drug Development Technology http://www.drugdevelopment-technology.com/content/images/logo_big.gif Akebia doses first patient in Phase II trial of vadadustat to treat DD-CKD http://www.drugdevelopment-technology.com/news/newsakebia-doses-first-patient-in-phase-ii-trial-of-vadadustat-to-treat-dd-ckd-5823907 http://www.drugdevelopment-technology.com/news/newsakebia-doses-first-patient-in-phase-ii-trial-of-vadadustat-to-treat-dd-ckd-5823907 US-based biopharmaceutical firm Akebia Therapeutics has started dosing patients in its Phase II FO2RWARD clinical trial of vadadustat for the treatment of patients with dialysis-dependent chronic kidney disease (DD-CKD). Wed, 24 May 2017 23:00:00 GMT Neurocrine’s Ingrezza fails to meet primary endpoint in Phase II trial for Tourette syndrome http://www.drugdevelopment-technology.com/news/newsneurocrines-ingrezza-fails-to-meet-primary-endpoint-in-phase-ii-trial-for-tourette-syndrome-5823901 http://www.drugdevelopment-technology.com/news/newsneurocrines-ingrezza-fails-to-meet-primary-endpoint-in-phase-ii-trial-for-tourette-syndrome-5823901 US-based biotechnology firm Neurocrine Biosciences’ Ingrezza (valbenazine) has failed to meet the primary endpoint in its Phase II T-Force GREEN clinical trial to treat Tourette syndrome. Wed, 24 May 2017 23:00:00 GMT Mallinckrodt begins enrolment in Phase IV trial of HP Acthar gel for RRMS http://www.drugdevelopment-technology.com/news/newsmallinckrodt-begins-enrolment-in-phase-iv-trial-of-hp-acthar-gel-for-rrms-5823104 http://www.drugdevelopment-technology.com/news/newsmallinckrodt-begins-enrolment-in-phase-iv-trial-of-hp-acthar-gel-for-rrms-5823104 UK-based specialist pharmaceutical firm Mallinckrodt has begun patient enrolment in the Phase IV OPTIONS clinical trial of HP Acthar gel to manage exacerbations in relapsing and remitting multiple sclerosis (RRMS) patients. Tue, 23 May 2017 23:00:00 GMT AstraZeneca’s Phase III trial shows benralizumab minimises OCS use in asthma patients http://www.drugdevelopment-technology.com/news/newsastrazenecas-phase-iii-trial-shows-benralizumab-minimises-ocs-use-in-asthma-patients-5822578 http://www.drugdevelopment-technology.com/news/newsastrazenecas-phase-iii-trial-shows-benralizumab-minimises-ocs-use-in-asthma-patients-5822578 AstraZeneca has reported positive results from its Phase III clinical trial of benralizumab in combination with standard-of-care treatment for patients with severe asthma. Tue, 23 May 2017 23:00:00 GMT UNS reports positive results from Phase I trial of UB-311 to treat Alzheimer’s disease http://www.drugdevelopment-technology.com/news/newsuns-reports-positive-results-from-phase-i-trial-of-ub-311-to-treat-alzheimers-disease-5822586 http://www.drugdevelopment-technology.com/news/newsuns-reports-positive-results-from-phase-i-trial-of-ub-311-to-treat-alzheimers-disease-5822586 United Neuroscience (UNS) has reported positive results from the Phase I clinical trial of UB-311 for the treatment of patients suffering from Alzheimer’s disease (AD). Tue, 23 May 2017 23:00:00 GMT ViaCyte to study PEC-Direct in international clinical trial for type 1 diabetes http://www.drugdevelopment-technology.com/news/newsviacyte-to-study-pec-direct-in-international-clinical-trial-for-type-1-diabetes-5821521 http://www.drugdevelopment-technology.com/news/newsviacyte-to-study-pec-direct-in-international-clinical-trial-for-type-1-diabetes-5821521 US-based regenerative medicine firm ViaCyte has obtained approval for its investigational new drug (IND) application from both the US Food and Drug Administration and Health Canada to initiate a clinical trial for investigating PEC-Direct in patients… Mon, 22 May 2017 23:00:00 GMT Celgene’s Phase III trial of ozanimod for RMS meets primary endpoint http://www.drugdevelopment-technology.com/news/newscelgenes-phase-iii-trial-of-ozanimod-for-rms-meets-primary-endpoint-5821274 http://www.drugdevelopment-technology.com/news/newscelgenes-phase-iii-trial-of-ozanimod-for-rms-meets-primary-endpoint-5821274 US-based biopharmaceutical firm Celgene has reported positive results from the Phase III RADIANCE clinical trial of ozanimod for the treatment of relapsing multiple sclerosis (RMS) patients. Mon, 22 May 2017 23:00:00 GMT Amgen’s Repatha shows positive outcome in Phase III trial for cardiovascular disease http://www.drugdevelopment-technology.com/news/newsamgens-repatha-shows-positive-outcome-in-phase-iii-trial-for-cardiovascular-disease-5821252 http://www.drugdevelopment-technology.com/news/newsamgens-repatha-shows-positive-outcome-in-phase-iii-trial-for-cardiovascular-disease-5821252 US-based biopharmaceutical firm Amgen has reported positive outcome for Repatha (evolocumab) in the Phase III FOURIER trial to treat patients suffering from cardiovascular disease. Mon, 22 May 2017 23:00:00 GMT Myovant reports positive data from Phase II trial of relugolix in Japan for endometriosis http://www.drugdevelopment-technology.com/news/newsmyovant-reports-positive-data-from-phase-ii-trial-of-relugolix-in-japan-for-endometriosis-5820361 http://www.drugdevelopment-technology.com/news/newsmyovant-reports-positive-data-from-phase-ii-trial-of-relugolix-in-japan-for-endometriosis-5820361 Myovant Sciences has reported positive results from the Phase II clinical trial of relugolix in Japan to treat pain associated with endometriosis in women. Sun, 21 May 2017 23:00:00 GMT Shire’s lanadelumab and SHP647 meet endpoints in respective trials http://www.drugdevelopment-technology.com/news/newsshires-lanadelumab-and-shp647-meet-endpoints-in-respective-trials-5820230 http://www.drugdevelopment-technology.com/news/newsshires-lanadelumab-and-shp647-meet-endpoints-in-respective-trials-5820230 Irish pharmaceutical company Shire has reported positive topline results from its Phase III HELP clinical trial of lanadelumab to treat hereditary angioedema (HAE) and from the Phase II TURANDOT trial of SHP647 (PF-00547659) for the treatment of ulce… Sun, 21 May 2017 23:00:00 GMT Albireo to initiate A4250’s Phase III clinical programme to treat PFIC http://www.drugdevelopment-technology.com/news/newsalbireo-to-initiate-a4250s-phase-iii-clinical-programme-to-treat-pfic-5820238 http://www.drugdevelopment-technology.com/news/newsalbireo-to-initiate-a4250s-phase-iii-clinical-programme-to-treat-pfic-5820238 Albireo Pharma is planning to initiate a Phase III clinical programme of its product candidate A4250 in the second half of this year for the treatment of patients with progressive familial intrahepatic cholestasis (PFIC). Sun, 21 May 2017 23:00:00 GMT Medical research funders and NGOs agree on new WHO clinical trial policies http://www.drugdevelopment-technology.com/news/newsmedical-research-funders-and-ngos-agree-on-new-who-clinical-trial-policies-5818523 http://www.drugdevelopment-technology.com/news/newsmedical-research-funders-and-ngos-agree-on-new-who-clinical-trial-policies-5818523 The majority of medical research funders and international non-governmental organisations (NGOs) have agreed to implement the new World Health Organisation (WHO) standards for clinical trials. Thu, 18 May 2017 23:00:00 GMT Deals this week: Genoa Pharmaceuticals, Dragonfly Therapeutics, Biomx http://www.drugdevelopment-technology.com/news/newsdeals-this-week-genoa-pharmaceuticals-inc-dragonfly-therapeutics-inc-biomx-ltd-5817270 http://www.drugdevelopment-technology.com/news/newsdeals-this-week-genoa-pharmaceuticals-inc-dragonfly-therapeutics-inc-biomx-ltd-5817270 US-based pharmaceutical company Genoa Pharmaceuticals has completed a series A venture financing round led by F-Prime Capital Partners and Edmond de Rothschild Investment Partners and participated by three other investors. Thu, 18 May 2017 23:00:00 GMT M&As this week: Thermo Fisher Scientific, Norgine http://www.drugdevelopment-technology.com/news/newsmas-this-week-thermo-fisher-scientific-inc-norgine-5817273 http://www.drugdevelopment-technology.com/news/newsmas-this-week-thermo-fisher-scientific-inc-norgine-5817273 US-based biotechnology company Thermo Fisher Scientific has reached an agreement to acquire Patheon through a tender offer for $35 a share in cash. Thu, 18 May 2017 23:00:00 GMT Aurinia begins voclosporin dosing in Phase III trial for LN http://www.drugdevelopment-technology.com/news/newsaurinia-begins-voclosporin-dosing-in-phase-iii-trial-for-ln-5818511 http://www.drugdevelopment-technology.com/news/newsaurinia-begins-voclosporin-dosing-in-phase-iii-trial-for-ln-5818511 Canadian-based biopharmaceutical firm Aurinia Pharmaceuticals has begun dosing patients in the Phase III AURORA clinical trial of voclosporin to treat lupus nephritis (LN). Thu, 18 May 2017 23:00:00 GMT Capecitabine improves post-surgery survival period in bile duct cancer patients http://www.drugdevelopment-technology.com/news/newscapecitabine-improves-post-surgery-survival-period-in-bile-duct-cancer-patients-5817763 http://www.drugdevelopment-technology.com/news/newscapecitabine-improves-post-surgery-survival-period-in-bile-duct-cancer-patients-5817763 A Cancer Research UK-funded trial (BILCAP) showed that the chemotherapy drug capecitabine increased the survival period of bile duct cancer patients by up to one and a half years after undergoing surgery for the disease. Wed, 17 May 2017 23:00:00 GMT Syndax’s entinostat advances into second stage of Phase II trial for NSCLC http://www.drugdevelopment-technology.com/news/newssyndaxs-entinostat-advances-into-second-stage-of-phase-ii-trial-for-nsclc-5817223 http://www.drugdevelopment-technology.com/news/newssyndaxs-entinostat-advances-into-second-stage-of-phase-ii-trial-for-nsclc-5817223 US-based biopharmaceutical firm Syndax Pharmaceuticals’ entinostat has advanced into the second stage of Phase II of the ENCORE 601 clinical trial for the treatment of patients with non-small cell lung cancer (NSCLC). Wed, 17 May 2017 23:00:00 GMT Interface Clinical Research develops new GP model to minimise clinical trial drop outs http://www.drugdevelopment-technology.com/news/newsinterface-clinical-research-develops-new-gp-model-to-minimise-clinical-trial-drop-outs-5817230 http://www.drugdevelopment-technology.com/news/newsinterface-clinical-research-develops-new-gp-model-to-minimise-clinical-trial-drop-outs-5817230 Interface Clinical Services’ division Interface Clinical Research has developed a new model to decrease the number of patient dropouts from clinical trials. Wed, 17 May 2017 23:00:00 GMT Syros starts dosing in Phase I trial of SY-1365 to treat solid tumours http://www.drugdevelopment-technology.com/news/newssyros-starts-dosing-in-phase-i-trial-of-sy-1365-to-treat-solid-tumours-5815827 http://www.drugdevelopment-technology.com/news/newssyros-starts-dosing-in-phase-i-trial-of-sy-1365-to-treat-solid-tumours-5815827 US-based biopharmaceutical company Syros Pharmaceuticals has started dosing patients in its Phase I clinical trial of SY-1365 for the treatment of patients with advanced solid tumours. Tue, 16 May 2017 23:00:00 GMT Actinogen begins enrolment in Phase II trial of Xanamem to treat Alzheimer’s disease http://www.drugdevelopment-technology.com/news/newsactinogen-begins-enrolment-in-phase-ii-trial-of-xanamem-to-treat-alzheimers-disease-5815838 http://www.drugdevelopment-technology.com/news/newsactinogen-begins-enrolment-in-phase-ii-trial-of-xanamem-to-treat-alzheimers-disease-5815838 Australian-based biotech firm Actinogen Medical has begun patient enrolment and dosing in the Phase II XanADu clinical trial of Xanamem for the treatment of Alzheimer's disease. Tue, 16 May 2017 23:00:00 GMT